California Nanotechnologies Corp.

As of May 31, 2026, California Nanotechnologies Corp carries a market capitalization of 8.95M, placing it among publicly traded companies globally. Its enterprise value stands at 9.71M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

California Nanotechnologies Corp's next confirmed earnings release is scheduled for November 2, 2026.

As of May 31, 2026, California Nanotechnologies Corp has 46.76M shares outstanding.

These figures are as of May 31, 2026. The price-to-sales ratio is 3.10, and the price-to-book ratio stands at 3.82.

These figures are as of May 31, 2026. The EV/Sales ratio of 3.32 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 9.71M versus a market cap of 8.95M, with the gap driven by net debt and cash on the balance sheet.

As of May 31, 2026, California Nanotechnologies Corp maintains a current ratio of 1.39, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 44.38, indicating elevated leverage, while an interest coverage ratio of -12.08 demonstrates limited ability to service its debt obligations.

Over the twelve months ended May 31, 2026, California Nanotechnologies Corp posted a negative return on equity (ROE) of -86.48, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -42.61, reflecting losses generated across the asset base. The company generates approximately 146,329.00 in revenue per employee across its workforce of 20.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended May 31, 2026, California Nanotechnologies Corp recorded 4,088.00 in income tax expense. The company reported a pretax loss of -2.01M and -2.01M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, California Nanotechnologies Corp's stock has declined approximately 7.66% over the past 52 weeks. The 50-day moving average sits at 0.26, while the 200-day moving average is 0.23.

Over the twelve months ended May 31, 2026, California Nanotechnologies Corp generated 2.93M in revenue and converted that into -2.01M in net income, yielding earnings per share of -0.04. EBITDA reached -1.43M, while operating income came in at -2.05M.

As of May 31, 2026, California Nanotechnologies Corp holds 275,062.00 in cash and equivalents against 1.04M in total debt, resulting in a net debt position of -275,062.00. Total book value stands at 2.34M, with working capital of 352,571.00 providing operational flexibility.

California Nanotechnologies Corp produced -611,376.00 in operating cash flow over the twelve months ended May 31, 2026. After subtracting -59,692.00 in capital expenditures, free cash flow totaled -671,068.00 - equivalent to -0.01 per share.

Over the twelve months ended May 31, 2026, California Nanotechnologies Corp posted a gross margin of 48.95, reflecting its pricing power and cost economics. The operating margin of -69.99 and net profit margin of -68.83 provide insight into operational efficiency.

These figures cover the twelve months ended May 31, 2026. Free cash flow yield is negative at -7.19: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.12, meaning California Nanotechnologies Corp raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of May 31, 2026, California Nanotechnologies Corp has an Altman Z-Score of 0.22, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.